In Vitro and In Vivo Genetic Disease Modeling via NHEJ-Precise Deletions Using CRISPR-Cas9
Authors:
Open Access
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 19, 426-437
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas
This publication has 24 references indexed in Scilit:
- CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type INature Communications, 2018
- A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome EditingCell Reports, 2018
- Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemiaNature Communications, 2017
- Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic diseaseScientific Reports, 2017
- On the Origin of CRISPR-Cas Technology: From Prokaryotes to MammalsTrends in Microbiology, 2016
- In vivoblunt-end cloning through CRISPR/Cas9-facilitated non-homologous end-joiningNucleic Acids Research, 2016
- Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophyNature Communications, 2015
- Crystal Structure of Cas9 in Complex with Guide RNA and Target DNACell, 2014
- AAV2 production with optimized N/P ratio and PEI-mediated transfection results in low toxicity and high titer for in vitro and in vivo applicationsJournal of Virological Methods, 2013
- Meganucleases and Other Tools for Targeted Genome Engineering: Perspectives and Challenges for Gene TherapyCurrent Gene Therapy, 2011